Abstract:The chemokine receptor CXCR4 plays an important role as the receptor for the normal physiological function of stromal cell-derived factor 1 alpha (SDF-1 alpha) and the coreceptor for the entry of human immunodeficiency virus type 1 (HIV-1) into the cell. In a recent work (S. Tian et al., J. Virol. 79:12667-12673, 2005), we found that many residues throughout CXCR4 transmembrane (TM) and extracellular loop 2 domains are specifically involved in interaction with HIV-1 gp120, as most of these sites did not play a role in either SDF-1 alpha binding or signaling. These results provided direct experimental evidence for the distinct functional sites on CXCR4 for HIV-1 and the normal ligand SDF-1 alpha. To further understand the CXCR4-ligand interaction and to develop new CXCR4 inhibitors to block HIV-1 entry, we have recently generated a new family of unnatural chemokines, termed synthetically and modularly modified (SMM) chemokines, derived from the native sequence of SDF-1 alpha or viral macrophage inflammatory protein II (vMIP-II). These SMM chemokines contain various de novo-designed sequence replacements and substitutions by D-amino acids and display more enhanced CXCR4 selectivity, binding affinities, and/or anti-HIV activities than natural chemokines. Using these novel CXCR4-targeting SMM chemokines as receptor probes, we conducted ligand binding site mapping experiments on a panel of site-directed mutants of CXCR4. Here, we provide the first experimental evidence demonstrating that SMM chemokines interact with many residues on CXCR4 TM and extracellular domains that are important for HIV-1 entry, but not SDF-1 alpha binding or signaling. The preferential overlapping in the CXCR4 binding residues of SMM chemokines with HIV-1 over SDF-1 alpha illustrates a mechanism for the potent HIV-1 inhibition by these SMM chemokines. The discovery of distinct functional sites or conformational states influenced by these receptor sites mediating different functions of the natural ligand versus the viral or synthetic ligands has important implications for drug discovery, since the sites shared by SMM chemokines and HIV-1 but not by SDF-1 alpha can be targeted for the development of selective HIV-1 inhibitors devoid of interference with normal SDF-1 alpha function.

Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, D-amino acid-containing SMM-chemokine ligand.

Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.

Critical role in CXCR4 signaling and internalization of the polypeptide main chain in the amino terminus of SDF-1α probed by novel N-methylated synthetically and modularly modified chemokine analogues.

Role Of Cxcr4 Internalization In The Anti-Hiv Activity Of Stromal Cell-Derived Factor-1 Alpha Probed By A Novel Synthetically And Modularly Modified-Chemokine Analog

Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains.

Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus Andd-Amino Acid-Containing Chemokine

Exploring the Stereochemistry of CXCR4-peptide Recognition and Inhibiting HIV-1 Entry with D-peptides Derived from Chemokines.

A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.

Marked structural and functional heterogeneity in CXCR4: Separation of HIV‐1 and SDF‐1α responses

Optimal Inhibition of X4 HIV Isolates by the CXC Chemokine Stromal Cell-derived Factor 1α Requires Interaction with Cell Surface Heparan Sulfate Proteoglycans*

A Novel Synthetic Chemokine Containing D-Amino Acids That Binds To The Cxcr4 Receptor And Inhibits Hiv-1 Infection

A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor Ccr5 Heterodimer: Binding Affinity Versus Functional Activities

Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

A Novel Peptide Antagonist of CXCR4 Derived from the N-Terminus of Viral Chemokine Vmip-Ii

Regulation of CXCR4 Receptor Dimerization by the Chemokine SDF-1α and the HIV-1 Coat Protein gp120: A Fluorescence Resonance Energy Transfer (FRET) Study

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands

Biological and mutational analyses of CXCR4-antagonist interactions and design of new antagonistic analogs

Computational Analysis of the Structural Mechanism of Inhibition of Chemokine Receptor CXCR4 by Small Molecule Antagonists

A New Class Of Chemokine Analogs As Useful Research Tools To Study Chemokine Receptor Function And Promising Therapeutic Agents.

A Novel CXCR4 Targeting Protein SDF-1/54 As an HIV-1 Entry Inhibitor.